Market Overview

Benzinga's Top Upgrades

Share:
Benzinga's Top Upgrades
Related BMY
SunTrust Names Eli Lilly, Merck, Bristol-Myers as 'Favorite' Pharma Firms
18 Biotech Stocks These Wall Street Analysts Are Tracking
Merck in $10B Buyback; Keytruda Tops Melanoma Study - Analyst Blog (Zacks)
Related GNRC
Generac Holdings CEO: Our Business Has Been Diversified
Morning-Market Movers Led By Oncolytics Biotech, Rite Aid & Pepsi

Analysts at Morgan Stanley upgraded Bristol-Myers Squibb Company (NYSE: BMY) from “equal-weight” to “overweight.” The target price for Bristol-Myers Squibb has been raised from $45 to $60. Bristol-Myers Squibb's shares closed at $48.77 on Friday.

Analysts at Goldman Sachs upgraded Generac Holdings (NYSE: GNRC) from “sell” to “neutral.” The target price for Generac Holdings has been raised from $32 to $49. Generac's shares closed at $50.44 on Friday.

Guggenheim Securities upgraded FMC Technologies (NYSE: FTI) from “neutral” to “buy.” The target price for FMC Technologies is set to $60. FMC Technologies' shares closed at $51.13 on Friday.

Analysts at Bank of America upgraded Astrazeneca PLC (NYSE: AZN) from “underperform” to “neutral.” Astrazeneca's shares closed at $52.74 on Friday.

Latest Ratings for BMY

DateFirmActionFromTo
Mar 2015Leerink SwannMaintainsOutperform
Mar 2015JP MorganMaintainsOverweight
Feb 2015Argus ResearchMaintainsBuy

View More Analyst Ratings for BMY
View the Latest Analyst Ratings

Posted-In: top upgradesUpgrades Analyst Ratings

 

Related Articles (AZN + BMY)

Around the Web, We're Loving...